Skip to main content

Advertisement

Table 2 Adverse events

From: Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial

Variable CLL (n = 12) DLBCL (n = 23) FL (n = 13) Overall (n = 48)
Number of patients with at least one AE 10 (83.3) 18 (78.3) 7 (53.8) 35 (72.9)
Number of AEs 71 45 25 141
Number of deaths 1 (8.3) 0 1 (7.7) 2 (4.2)
Number of patients withdrawn from study due to an AE 1 (8.3) 0 0 1 (2.1)
Number of patients with at least one
 AE with fatal outcome 1 (8.3) 0 0 1 (2.1)
 SAE 5 (41.7) 3 (13.0) 1 (7.7) 9 (18.8)
 SAE leading to withdrawal from treatment 1 (8.3) 0 0 1 (2.1%)
 Related SAE 4 (33.3) 1 (4.3) 1 (7.7) 6 (12.5)
 AE leading to withdrawal from treatment 1 (8.3) 0 0 1 (2.1)
 AE leading to treatment interruption 4 (33.3) 3 (13.0) 2 (15.4) 9 (18.8)
 Related AE 9 (75.0) 12 (52.2) 7 (53.8) 28 (58.3)
 Related AE leading to treatment interruption 4 (33.3) 3 (13.0) 2 (15.4) 9 (18.8)
 Grade III–V AE (at greatest intensity) 7 (58.3) 5 (21.7) 3 (23.1) 15 (31.3)
  1. Percentages are based on n in the column headings. Multiple occurrences of the same AE in one individual are counted only once except for the ‘total number of AEs’ row, in which multiple occurrences of the same AE are counted separately
  2. Data are shown as n (%)
  3. AE adverse event, CLL chronic lymphocytic leukemia, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, SAE serious adverse event